J Clin Invest 122: 388-402, 2012
R., Hermansen, K
10.1111/j.1742-1241.2011.02656.x Summary Keywords incretin hormones, GLP-1 receptor agonists, DPP-4 inhibitors, cardiovascular outcomes trials, clinical trials, incretin biology, type 2 diabetes Citation Gilbert MP and Pratley RE (2020) GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Approval status Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine - neither is on the Australian Register of Therapeutic Goods, and the TGA has not evaluated either for safety, quality or effectiveness
Interestingly, we found that the IML in C8-T2 does not receive a more robust GLP-1 innervation than in other segments where SPNs do not express GLP-1R, and GLP-1 fibers seldom contacted the cell bodies or proximal dendrites of GLP-1R + SPNs